Bile duct cancer combo trial halted early

NCT ID NCT05998447

Terminated Disease control Sponsor: Genome & Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug combination (GEN-001 plus pembrolizumab) in 10 adults with advanced bile duct cancer that had stopped responding to standard treatments. The goal was to see if the combination was safe and could shrink tumors. The trial was terminated early, so final results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer Biliary Tract Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BILIARY TRACT CANCER

Contacts and locations

Show contact details

Locations

Ajou University Medical Center

Suwon, 16499, South Korea
Asan Medical Center

Seoul, Seoul, 05505, South Korea
Korea University Guro Hospital

Seoul, Seoul, 08308, South Korea
Samsung Medical Center.

Seoul, Seoul, 06351, South Korea
Seoul National University Hospital

Seoul, Seoul, 03080, South Korea
Severance Hospital

Seoul, Seoul, 03722, South Korea